CALGB 30607: Randomized, Phase III, Double-Blind Placebo Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Aims: The purpose of this study is to determine whether treatment with a drug called sunitinib after you respond to chemotherapy (your tumor shrinks or stops growing) will help your tumor continue to shrink or stay the same. Sunitinib is investigational in the treatment of non-small cell lung cancer. Standard treatment for this type of cancer after initial therapy is to stop chemotherapy treatment or use the drug pemetrexed. In this study, you will get either sunitinib or the placebo (a substance that looks like sunitinib, but contains no medication).
Diagnosis: Stage IIIB/IV Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH09-088
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Aims: The purpose of this study is to compare the effects, good and/or bad, of three different ways to give radiation therapy. Two of the ways are investigational, while one of them is standard. The two investigational ways of giving the radiation therapy are: (1) once a day with a high dose of radiation for 7 weeks; or (2) once a day for 16 days of treatment (about 3 weeks), followed by twice a day for the remaining 9 days of treatment (about 2 weeks), for a total of 5 weeks. The standard way of giving the radiation therapy is to give it twice a day for 3 weeks. In addition, all participants will receive chemotherapy with cisplatin and etoposide, the standard drugs for this type of cancer.
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH08-417
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with our without Bevacizumab for Patients with Completely Resected Stage IB (>4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure in patients who have had surgery to remove their lung cancer. Bevacizumab works by preventing the formation of new blood vessels that supply cancer cells with the oxygen and nutrients they need to survive and grow. By taking away the blood supply, drugs like bevacizumab (also called angiogenesis inhibitors) may reduce tumor cell growth or cause cancerous tumors to grow more slowly or to become smaller. This study will compare the effects (good and bad) of adding bevacizumab to chemotherapy with those of standard chemotherapy alone.
Diagnosis: Stage IB (>4cm) - IIIA Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH07-393
Sponsor: Eastern Cooperative Oncology Group
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

UC10-014B: A Randomized, Open-Label, Dose Escalation Study of Bevacizumab with Ambulatory Blood Pressure Monitoring in Previously Untreated Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Aims: The purpose of this study is to better understand what effect the dose of a drug called bevacizumab has on side effects and lung cancer.  In particular, the doctors directing this research are interested in looking at how the dose of bevacizumab will affect a patient's blood pressure.  In some patients, a higher dose of bevacizumab might do more damage to the tumor.  In other patients, a higher dose might only cause more side effects and a lower dose might do the same amount of damage to the tumor. The study aims to determine which dose is best to use for each patient.
Diagnosis: Advanced Non-Squamous Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH11-234
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
Aims: This research is being done because current standard treatments for advanced non-small cell lung cancer are not effective in preventing the cancer from growing in most cases. The purpose of this study is to compare the effects, good and/or bad, of adding the experimental drug celecoxib to standard chemotherapy.  It is thought that cancers with high levels of  a certain enzyme called COX-2 may benefit from the addition of celecoxib to standard chemotherapy. In this study, all participants will have a test performed on their tumor specimens to find out if their tumor has high levels of COX-2. Only patients with a high level of COX-2 will continue with treatment on this trial and recieve celecoxib or a placebo.
Diagnosis: Advanced Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH12-250
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

CALGB 140503: A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (< 2cm) Peripheral Non-Small Cell Lung Cancer
Aims: The clinical trial will be studying the overall effects (good and/or bad) of a sublobar resection (removing a small portion of the lung) compared to a lobectomy (removing entire lobe of the lung) when it comes to preserving lung function and prevention of lung cancer recurrence after surgery. Subjects with non small cell lung cancer tumor less than 2 cm in size and lcoated in the periphery of the lung will be randomized to either sublobar or lobectomy surgery.
Diagnosis: Lung Cancer
Principal Investigator: John Howington, MD
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: For more information, interested participants may contact Agnes Brugger, Clinical Research Nurse at 847.570.1871
Open to Enrollment: Yes

× Alternate Text